

## SIMPONI® (golimumab)

recommended for 6 months following the mother's last SIMPONI injection during pregnancy (see *Use in Specific Populations*). **Cytochrome P450 Substrates** The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNF $\alpha$ ) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of SIMPONI® in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. **USE IN SPECIFIC POPULATIONS: Pregnancy** Pregnancy Category B – There are no adequate and well-controlled studies of SIMPONI® in pregnant women. Because animal reproduction and developmental studies are not always predictive of human response, it is not known whether SIMPONI® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. SIMPONI® should be used during pregnancy only if clearly needed. An embryofetal developmental toxicology study was performed in which pregnant cynomolgus monkeys were treated subcutaneously with golimumab during the first trimester with doses up to 50 mg/kg twice weekly (360 times greater than the maximum recommended human dose-MHRD) and has revealed no evidence of harm to maternal animals or fetuses. Umbilical cord blood samples collected at the end of the second trimester showed that fetuses were exposed to golimumab during gestation. In this study, *in utero* exposure to golimumab produced no developmental defects to the fetus. A pre- and post-natal developmental study was performed in which pregnant cynomolgus monkeys were treated with golimumab during the second and third trimesters, and during lactation at doses up to 50 mg/kg twice weekly (860 times and 310 times greater than the maximal steady state human blood levels for maternal animals and neonates, respectively) and has revealed no evidence of harm to maternal animals or neonates. Golimumab was present in the neonatal serum from the time of birth and for up to six months postpartum. Exposure to golimumab during gestation and during the postnatal period caused no developmental defects in the infants. IgG antibodies are known to cross the placenta during pregnancy and have been detected in the serum of infants born to patients treated with these antibodies. Since SIMPONI is an IgG antibody, infants born to women treated with SIMPONI during their pregnancy may be at increased risk of infection for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI *in utero* is not recommended for 6 months following the mother's last SIMPONI injection during pregnancy (see Warnings and Precautions). **Nursing Mothers** It is not known whether SIMPONI® is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for adverse reactions in nursing infants from SIMPONI®, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In the pre- and post-natal development study in cynomolgus monkeys in which golimumab was administered subcutaneously during pregnancy and lactation, golimumab was detected in the breast milk at concentrations that were approximately 400-fold lower than the maternal serum concentrations. **Pediatric Use** Safety and effectiveness of SIMPONI® in patients less than 18 years of age have not been established. **Geriatric Use** In the Phase 3 trials in RA, PsA, and AS, there were no overall differences in SAEs, serious infections, and AEs in SIMPONI®-treated patients ages 65 or older (N=155) compared with younger SIMPONI®-treated patients. Because there is a higher incidence of infections in the geriatric population in general, caution should be used in treating geriatric patients with SIMPONI®. **OVERDOSAGE** In a clinical study, 5 patients received protocol-directed single infusions of 10 mg/kg of intravenous SIMPONI® without serious adverse reactions or other significant reactions. The highest weight patient was 100 kg, and therefore received a single intravenous infusion of 1000 mg of SIMPONI®. There were no SIMPONI® overdoses in the clinical studies. **PATIENT COUNSELING INFORMATION Patient Counseling** Patients should be advised of the potential benefits and risks of SIMPONI®. Physicians should instruct their patients to read the Medication Guide before starting SIMPONI® therapy and to read it each time the prescription is renewed. **Infections** Inform patients that SIMPONI® may lower the ability of their immune system to fight infections. Instruct the patient of the importance of contacting their doctor if they develop any symptoms of infection, including tuberculosis, invasive fungal infections, and hepatitis B reactivation. **Malignancies** Patients should be counseled about the risk of lymphoma and other malignancies while receiving SIMPONI®. **Allergic Reactions** Advise latex-sensitive patients that the needle cover on the prefilled syringe as well as the prefilled syringe in the prefilled SmartJect® autoinjector contains dry natural rubber (a derivative of latex). **Other Medical Conditions** Advise patients to report any signs of new or worsening medical conditions such as congestive heart failure, demyelinating disorders, autoimmune diseases, liver disease, cypotenias, or psoriasis.

**REFERENCES:** 1. SEER [database online]. U.S. Population Data—1969-2004. Bethesda, MD; National Cancer Institute. Release date: January 3, 2007. Available at: <http://www.seer.cancer.gov/popdata>.

© Janssen Biotech, Inc. 2011 US License No. 1864  
Horsham, PA 19044 1-800-457-6399 Revised: 9/2011 25SM11035

# eventos

## Se llevó a cabo la Subasta de Arte Benéfica 'Mecenas' de la Universidad Central del Caribe en el Colegio de Arquitectos de Puerto Rico.



Manuel Arbona; Joaquín Arbona Lago, Presidente Junta Síndicos UCC; Dr. José Ginel Rodríguez; Jaritza Ubiñas y Emilia Soto.



Dr. José Ginel Rodríguez, Presidente UCC; Celina Nogueras-Cuevas y José Fernando Vázquez.



María Rosa Beale e Yvonne Corsino, Directora de la Subasta.



(de pie) Edna Brayfield, Janice Rodríguez, Elizabeth Pérez, Vivian Valiente, Ariel Grajales, (sentadas) Lucía Nogueras e Ineabelle López.